IP Infusion Announces Record-Breaking Growth Surge in First Quarter of 2023

IP Infusion, a leading provider of open network software and solutions for wireline and mobile network operators, announced today that the company is experiencing sustained record-breaking growth, with 1Q 2023 sales the highest ever for a single quarter. This year's first quarter OcNOS® sales orders are more than three times Year over Year compared to Q1 2022, led by robust demand for OcNOS's disaggregated Data Center, Aggregation Router and Cell Site Router products.

In addition, 23 new customers in the first quarter chose OcNOS, the industry's first and preferred full-featured modular extensible network OS designed for white box open networking solutions. New customer announcements include Netplus Broadband, MetaLINK Technologies, Amplex Internet, Broadstar, Multinet, and Pine Networks. IP Infusion also announced in Q1 2023 that it collaborated with NTT Corporation (NTT) for the development of Beluganos, a new network operating system to realize NTT's IOWN concept, and is providing sales and support for its global markets.

"IP Infusion is proud to report yet another unequaled quarter of sales growth fueled by a powerful demand for our industry-acclaimed OcNOS products," said Atsushi Ogata, President and CEO of IP Infusion. "This solid performance reflects our commitment to exceed expectations for delivering the most advanced disaggregated solutions to our expanding customer base and partners across the globe."

About IP Infusion

IP Infusion manufactures open network software and solutions for carriers, service providers, and data centers. With hundreds of customers and thousands of deployments, IP Infusion is a market leader in Network Operating Systems. Our flagship software platform OcNOS® allows network operators to disaggregate their networks, streamline operations, and reduce Total Cost of Ownership (TCO). Network OEMs may also disaggregate network devices to expedite time to market, offer comprehensive services, and achieve carrier-grade robustness.

IP Infusion is headquartered in Santa Clara, Calif., and is a wholly owned and independently operated subsidiary of ACCESS CO., LTD. Additional information can be found at http://www.IPInfusion.com.

IP Infusion and OcNOS are trademarks or registered trademarks of IP Infusion. ACCESS is a registered trademark or trademark of ACCESS CO., LTD. in the United States, Japan and/or other countries. Northforge Innovations is a registered trademark of Northforge Innovations, Inc. All other trademarks, service marks, registered trademarks, or registered service marks mentioned are the property of their respective owners.